Non-Small Cell Lung Cancer (NSCLC) -
Conditions
Interventions
Experimental: Selpercatinib
Selpercatinib administered orally.
Placebo Comparator: Placebo
Placebo administered orally.
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Must have histologically confirmed Stage IB, II, or IIIA NSCLC. 2. Must have an activating RET gene fusion in tumor based on polymerase chain reaction (PCR) or next generation sequencing (NGS). 3. Must have received definitive locoregional therapy with curative intent (surgery or radiotherapy) for Stage IB, II, or IIIA NSCLC. (Receipt of systemic anti-cancer therapy is allowed but not required.) 4. Must have completely recovered from definitive therapy (surgery or radiotherapy) as well as adjuvant therapy at the time of randomization. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 6. Adequate hematologic, hepatic, and renal function. 7. Willingness of men and women of reproductive potential to observe conventional and highly effective birth control for the duration of the study.
Exclusion criteria
Exclusion criteria: 1. Additional oncogenic drivers in NSCLC, if known. 2. Evidence of small cell lung cancer. 3. Clinical or radiologic evidence of disease recurrence or progression following definitive therapy. 4. Known or suspected interstitial fibrosis or interstitial lung disease or history of (noninfectious) pneumonitis that required steroids. 5. Clinically significant active cardiovascular disease or history of myocardial infarction within six months prior to planned start of selpercatinib or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) greater than 470 milliseconds. 6. Have known uncontrolled human immunodeficiency virus (HIV)-1/2 infection. 7. Have known active hepatitis B or C. 8. Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. 9. Major surgery within 4 weeks prior to planned start of selpercatinib. 10. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug. 11. Other malignancy unless nonmelanoma skin cancer, carcinoma in situ of the cervix or other in situ cancers or a malignancy diagnosed greater than or equal to two years previously and not currently active. 12. Pregnancy or lactation. 13. Prior treatment with a selective RET inhibitor (e.g. selpercatinib or pralsetinib).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-Free Survival (EFS) [ Time Frame: Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years) ] EFS by Investigator Assessment in the Primary Analysis Population | — |
Countries
Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Singapore, South Korea, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed